Skip to content

Abnormal Circulating C Peptide Concentration C4280765

Published: July 22, 2026Updated: August 26, 2026

C-peptide is released with insulin and shows how much insulin the body produces. Abnormal levels help differentiate between type 1 and type 2 diabetes and assess insulin production. Treatment depends on the diabetes type and severity.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 26, 2026Editorial policy

Key facts at a glance

ICD-10
E34.9
ICD-11
5A00.0
Body system
endocrine
Severity
moderate
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Loss of consciousness

Fainting or passing out, often related to severe blood sugar fluctuations.

Seek immediate emergency care if someone loses consciousness

!

Seizures

Involuntary muscle movements and loss of awareness due to severe hypoglycemia.

Seek immediate emergency care for any seizure activity

Fatigue

(constitutional)

Persistent tiredness and lack of energy that interferes with daily activities.

Frequency: 70-80% of patients

Difficulty concentrating

(neurologic)

Trouble focusing, mental fog, or reduced ability to perform complex tasks.

Frequency: 65-75% of patients

Excessive sweating

(autonomic)

Unusual sweating, especially at night or without obvious cause.

Frequency: 60-70% of patients

Palpitations

(cardiovascular)

Awareness of rapid, strong, or irregular heartbeat.

Frequency: 40-50% of patients

Tremor

(neurologic)

Shaking or trembling, often noticeable in the hands.

Frequency: 35-45% of patients

Increased hunger

(gastrointestinal)

Excessive feeling of hunger, even after eating meals.

Frequency: 40-50% of patients

Dizziness

(neurologic)

Feeling of lightheadedness, unsteadiness, or faintness.

Frequency: 30-40% of patients

Blurred vision

(neurologic)

Temporary vision changes or difficulty focusing clearly.

Frequency: 20-30% of patients

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Endocrine management

Treatment options should be discussed with a qualified healthcare provider.

lifestyle
2

Glucose regulation through exercise

Regular physical activity improves insulin sensitivity and helps regulate blood glucose levels, which can normalize C-peptide production. Moderate aerobic exercise 150 minutes weekly combined with resistance training is recommended.

lifestyle
3

Carbohydrate-controlled meal planning

Structured carbohydrate intake with consistent timing helps stabilize insulin secretion and C-peptide levels. Focus on low glycemic index foods and balanced macronutrient distribution throughout the day.

dietary

Additional treatment options

Insulin sensitizing agents

Medications that improve cellular response to insulin may help normalize C-peptide levels when lifestyle measures are insufficient. Treatment selection depends on underlying etiology and overall metabolic profile.

medication

Metabolic laboratory tracking

Serial measurements of C-peptide alongside glucose levels help assess treatment response and guide therapeutic adjustments. Monitoring frequency depends on clinical stability and treatment changes.

monitoring

Stress management techniques

Chronic stress elevates cortisol and affects glucose metabolism, indirectly influencing C-peptide levels. Mind-body practices such as meditation and breathing exercises support overall metabolic balance.

complementary

When to seek medical help

Recognize when you need immediate medical attention.

Schedule an appointment soon

Symptoms associated with this condition. Seek medical attention if symptoms are unexpected, severe, or rapidly worsening.- Contact your healthcare provider if symptoms persist or worsen. Seek emergency care for sudden severe symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Abnormal Circulating C Peptide Concentration C4280765?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2023. Diabetes Care. 2023;46(Suppl_1):S19-S40.

guideline2023View source →
2

Jones AG, Hattersley AT. The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabet Med. 2013;30(7):803-817.

review2013View source →
3

World Health Organization. Classification of Diabetes Mellitus 2019. Geneva: World Health Organization; 2019.

guideline2019View source →
4

American Diabetes Association. 6. Glycemic Targets: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022;45(Suppl_1):S83-S96.

position_statement2022View source →
5

Leighton E, Sainsbury CA, Jones GC. A Practical Review of C-Peptide Testing in Diabetes. Diabetes Ther. 2017;8(3):475-487.

review2017View source →
6

Palmer JP, Fleming GA, Greenbaum CJ, et al. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2004. Diabetes. 2004;53(1):250-264.

clinical_trial2004View source →
7

Bogun MM, Bundy BN, Goland RS, Greenbaum CJ. C-Peptide Levels in Subjects With Newly Diagnosed Type 1 Diabetes Before and After Immunotherapy. J Clin Endocrinol Metab. 2020;105(3):dgz204.

meta_analysis2020View source →
8

Melmed S, Polonsky KS, Larsen PR, Kronenberg HM. Williams Textbook of Endocrinology. 14th ed. Philadelphia: Elsevier; 2019.

textbook2019
9

International Society for Pediatric and Adolescent Diabetes. ISPAD Clinical Practice Consensus Guidelines 2022. Pediatr Diabetes. 2022;23(8):1179-1199.

consensus2022View source →
10

Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2022. Atlanta, GA: CDC; 2022.

Medication Comparisons

Compare medications used to treat Abnormal Circulating C Peptide Concentration C4280765. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 26, 2026. · Read our editorial policy